Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Sell
20
NCNA Quote, Financials, Valuation and Earnings
Last price:
$0.82
Seasonality move
:
-24.5%
Day range:
$0.79 - $0.85
52-week range:
$0.75 - $10.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.54x
Volume:
31.1K
Avg. volume:
41.2K
1-year change:
-90.3%
Market cap:
$3.2M
Revenue:
--
EPS (TTM):
-$14.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$2.20 | -- | -98.11% | $64.50 |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.40 |
|
BCYC
Bicycle Therapeutics PLC
|
$5.5M | -$0.85 | -55.59% | -31.65% | $29.55 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
VRNA
Verona Pharma PLC
|
$33.5M | -$0.15 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
$0.81 | $64.50 | $3.2M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$1.68 | $10.40 | $445.8M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$9.49 | $29.55 | $656.7M | -- | $0.00 | 0% | 15.65x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$2.00 | $17.97 | $1.3M | -- | $0.00 | 0% | 1.80x |
|
TCBP
TC BioPharm (Holdings) PLC
|
$1.54 | -- | $790K | -- | $0.25 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$66.09 | $81.00 | $5.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.987 | -- | 17.97x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 0.789 | -- | 13.61x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
NuCana PLC vs. Competitors
-
Which has Higher Returns NCNA or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -522.15%. NuCana PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About NCNA or AUTL?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 7892.57%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.40 which suggests that it could grow by 520.9%. Given that NuCana PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe NuCana PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 1 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is NCNA or AUTL More Risky?
NuCana PLC has a beta of 0.892, which suggesting that the stock is 10.789% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.067, suggesting its more volatile than the S&P 500 by 106.723%.
-
Which is a Better Dividend Stock NCNA or AUTL?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or AUTL?
NuCana PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. NuCana PLC's net income of -$5.9M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, NuCana PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns NCNA or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -1398.44%. NuCana PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -26.21%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M -
What do Analysts Say About NCNA or BCYC?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 7892.57%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 211.33%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 1 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is NCNA or BCYC More Risky?
NuCana PLC has a beta of 0.892, which suggesting that the stock is 10.789% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.
-
Which is a Better Dividend Stock NCNA or BCYC?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BCYC?
NuCana PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $3.7M. NuCana PLC's net income of -$5.9M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, NuCana PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 15.65x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M BCYCBicycle Therapeutics PLC15.65x -- $3.7M -$51.9M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About NCNA or BDRX?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 7892.57%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 804.58%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 1 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is NCNA or BDRX More Risky?
NuCana PLC has a beta of 0.892, which suggesting that the stock is 10.789% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 1.80x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M BDRXBiodexa Pharmaceuticals PLC1.80x -- -- --
-
Which has Higher Returns NCNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About NCNA or TCBP?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 7892.57%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 3016.88%. Given that NuCana PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe NuCana PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 1 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is NCNA or TCBP More Risky?
NuCana PLC has a beta of 0.892, which suggesting that the stock is 10.789% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NCNA or TCBP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. NuCana PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or TCBP?
NuCana PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, NuCana PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns NCNA or VRNA?
Verona Pharma PLC has a net margin of -- compared to NuCana PLC's net margin of -92.29%. NuCana PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About NCNA or VRNA?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 7892.57%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 22.56%. Given that NuCana PLC has higher upside potential than Verona Pharma PLC, analysts believe NuCana PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 1 0 VRNAVerona Pharma PLC5 0 0 -
Is NCNA or VRNA More Risky?
NuCana PLC has a beta of 0.892, which suggesting that the stock is 10.789% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock NCNA or VRNA?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or VRNA?
NuCana PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. NuCana PLC's net income of -$5.9M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, NuCana PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
58
SIG alert for Mar 21
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
43
HQY alert for Mar 21
HealthEquity [HQY] is up 0.28% over the past day.
